Zobrazeno 1 - 10
of 221
pro vyhledávání: '"Anthony J, Olszanski"'
Autor:
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti‐PD‐1 therapy in cancer models. This dose‐escalation/expansion study inv
Externí odkaz:
https://doaj.org/article/543c6b5130f7472f8fd3b9ea9ea6f7e2
Autor:
Aranzazu Manzano, Omid Hamid, Emiliano Calvo, Marc S Ernstoff, Anthony J Olszanski, John Wrangle, Anthony F Shields, Stephen V Liu, Sarina A Piha-Paul, Trisha M Wise-Draper, Yangchun Du, Justin A Call, Shwetha Asha, Ralph Boccia, Angela Tatiana Alistar, Carlos Mayo, Leah Rider
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/244450926eae4f87ad823e24d4edc673
Autor:
Jason Luke, Ahmad A Tarhini, Anthony J Olszanski, Chen Zhu, Giovanni Abbadessa, Christos Fountzilas, Lee Rosen, Adyb Baakili, Timothy Wagenaar, Helene Guillemin-Paveau, Meijing Wu, Raymond Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/a465a0cc05d4460c930f0556208712da
Publikováno v:
Cancer Biology & Therapy, Vol 23, Iss 1, Pp 117-126 (2022)
Mitochondria are key tumor drivers, but their suitability as a therapeutic target is unknown. Here, we report on the preclinical characterization of Gamitrinib (GA mitochondrial matrix inhibitor), a first-in-class anticancer agent that couples the He
Externí odkaz:
https://doaj.org/article/323440b459744844bcf3002c13b30f4e
Autor:
Victor Moreno, Andrew Gerry, Tom Holdich, Anthony J Olszanski, Ramaswamy Govindan, John V Heymach, Matthew J Frigault, Siddhartha Devarakonda, Melissa Johnson, Justin Gainor, Carlos Bachier, Natalie Hyland, Jean-Marc Navenot, Svetlana Fayngerts, Jane Bai, Elliot Norry, Robyn Broad, George R Blumenschein, Martin J Edelman, Bernard Doger de Spéville, Vincent K Lam, Zohar Wolchinsky, Dzmitry Batrakou, Melissa M Pentony, Joseph P Sanderson, Diane Marks, Paula M Fracasso
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/bb48deb4a4b44ce99c7898cce61aa878
Autor:
Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-
Externí odkaz:
https://doaj.org/article/5099b0af01e64192a7b84fc9a960caa6
Autor:
Lisa A. Kottschade, Gregory Russell Pond, Anthony J. Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J. Hauke, Brendan D. Curti, Sarah Schober, Mohammed M. Milhem, Matthew Stephen Block, Tina Hieken, Robert R. McWilliams
Publikováno v:
Clinical Cancer Research. :OF1-OF6
Purpose: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f17632ed77ac64bf22946772a46e3ef1
https://doi.org/10.1158/1078-0432.ccr-22-3207
https://doi.org/10.1158/1078-0432.ccr-22-3207
Autor:
David S. Hong, Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski, Jeffrey M. Clarke, Dejka Araujo, George R. Blumenschein, Partow Kebriaei, Quan Lin, Alex J. Tipping, Joseph P. Sanderson, Ruoxi Wang, Trupti Trivedi, Thejo Annareddy, Jane Bai, Stavros Rafail, Amy Sun, Lilliam Fernandes, Jean-Marc Navenot, Frederic D. Bushman, John K. Everett, Derin Karadeniz, Robyn Broad, Martin Isabelle, Revashnee Naidoo, Natalie Bath, Gareth Betts, Zohar Wolchinsky, Dzmitry G. Batrakou, Erin Van Winkle, Erica Elefant, Armin Ghobadi, Amanda Cashen, Anne Grand’Maison, Philip McCarthy, Paula M. Fracasso, Elliot Norry, Dennis Williams, Mihaela Druta, David A. Liebner, Kunle Odunsi, Marcus O. Butler
Publikováno v:
Nature Medicine. 29:104-114
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3bcb18cec08cabb466f42330474d0ce
https://doi.org/10.1038/s41591-022-02128-z
https://doi.org/10.1038/s41591-022-02128-z
Autor:
Jeanne Tie, Dirk Jäger, Victor Moreno, Dirk Nagorsen, Gloria Juan, Kyriakos P Papadopoulos, Anthony J Olszanski, Erik Rasmussen, Nehal Lakhani, Albiruni RA Razak, James M Cleary, Michael Boyer, Emiliano Calvo Aller, William Edenfield, R Donald Harvey, Annemie Rutten, Manish A Shah, David P Ryan, Hansen Wong, Neelesh Soman, Marie-Anne Damiette Smit
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background To determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors.Patients and methods Patients had advance
Externí odkaz:
https://doaj.org/article/c86d4e961e1c408ea5c8168b4d7c83df
Autor:
Alexander N. Shoushtari, Anthony J. Olszanski, Marta Nyakas, Thomas J. Hornyak, Jedd D. Wolchok, Victor Levitsky, Lukasz Kuryk, Thomas B. Hansen, Magnus Jäderberg
Publikováno v:
Clinical Cancer Research. 29:100-109
Purpose: Intratumoral oncolytic virotherapy may overcome anti–PD(L)-1 resistance by triggering pro-inflammatory remodeling of the tumor microenvironment. This pilot study investigated ONCOS-102 (oncolytic adenovirus expressing GM-CSF) plus anti–p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06be8a8edad3429d33a9dee13af7045b
https://doi.org/10.1158/1078-0432.ccr-22-2046
https://doi.org/10.1158/1078-0432.ccr-22-2046